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Introduction
The last Congress of the European Society of Cardiology, 
the world’s largest meeting for cardiologists, took place 
from 31st August to 4th September 2019, together with the 
World Congress of Cardiology. It was held in one of the 
most charming European capitals — Paris. Among the many 
interesting thematic lectures, the participants were most 
interested in hotline sessions, which presented the results 
of the latest, long-awaited clinical cardiology research, 
including innovative treatments using new drugs.
This congress abounded in breakthrough scientific 
reports which, in the near future, may change the phar-
macotherapy standards of the most common diseases 
in cardiology — heart failure (HF) and coronary artery 
disease (CAD). Of the many relevant clinical trials, the 
most interesting ones that may have practical application 
are described below.
DAPA-HF — dapagliflozin  
as a new effective drug in HF?
One of the most important studies presented to cardiolo-
gists for the first time was DAPA-HF (Study to Evaluate the 
Effect of Dapagliflozin on the Incidence of Worsening Heart 
Failure or Cardiovascular Death in Patients With Chronic 
Heart Failure) [1], a study on the use of dapagliflozin — an 
inhibitor sodium-glucose co-transporter 2 (SGLT2) as a drug 
in HF. Researchers examined whether adding dapagliflozin 
10 mg OD to standard pharmacotherapy would benefit pa-
tients with reduced left ventricular ejection fraction (LVEF), 
regardless of the type 2 diabetes mellitus (T2DM). The 
study included patients with HF symptoms in II, III, IV failure 
class according to the New York Heart Association (NYHA), 
LVEF not more than 40% and a minimum concentration of 
the N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
higher than or equal to 600 pg/mL, as well as greater than 
or equal to 400 pg/mL, when they were hospitalised due 
to HF during last 12 months or at least 900 pg/mL for co-
-existing atrial fibrillation or flutter. Exclusion criteria were 
chronic kidney disease and estimated glomerular filtration 
rate (eGFR) less than 30 mL/min/1.73 m2, symptomatic 
arterial hypotension with systolic blood pressure (SBP) 
less than 95 mm Hg, or type 1 diabetes mellitus. During 
the 14-day initial assessment, researchers analysed the 
inclusion and exclusion criteria for patients from the study. 
After this period, patients were divided into groups receiving 
dapagliflozin or placebo. The further diagnostic evaluation 
followed 14 or 60 days after inclusion. Additional visits 
took place after 4 months, and then every 4 months (from 
February 15, 2017 to August 17, 2018). The primary end-
point was an exacerbation of HF symptoms associated with 
unplanned hospitalization or requiring intravenous diuretic 
therapy, as well as cardiovascular death. Of the initially 
evaluated 8,134 patients from 20 countries, 4,744 patients 
were randomised, including 2,373 patients treated with 
dapagliflozin. The study brought ground-breaking results; 
dapagliflozin, developed as a hypoglycaemic drug, has been 
273www.journals.viamedica.pl/folia_cardiologica
Kamila Cygulska, Jarosław D. Kasprzak, Heart failure and anticoagulation — at the ESC 2019
4,822 patients aged 50 years and from 43 countries with 
persistent HF symptoms in NYHA and LVEF class II–IV not 
less than 45% and elevated NT-proBNP concentration. 
Individuals were excluded with acute, decompensated HF, 
LVEF below 40%, SBP values below 110 mm Hg or above 
180 mm Hg, and SBP above 150 mm Hg if patients did not 
take more than 3 antihypertensive drugs. Researchers failed 
to reach the primary endpoint — only the benefit trend of the 
new therapy was obtained (reduction of hospitalisations and 
cardiovascular death by 13%, p = 0.059). Similarly, there 
was a trend to reduce the risk of hospitalisation in the key 
ARNI group (690 vs. 797 in the valsartan group; relative 
risk [RR] 0.85, p = 0.056). Among the secondary endpoints, 
there was a statistically significant improvement in clinical 
status in the ARNI-treated group compared to ARB-treated 
patients [odds ratio (OR) 1.35, p = 0.004], also confirmed 
on the KCCQ quality of life scale (OR = 1.3, p = 0.019). 
Protective effects on kidney function have also been ob-
served [HR = 0.55; 95% confidence interval (CI) 0.33–0.77, 
p = 0.002]. In the group of patients undergoing complex 
therapy, a higher tendency to hypotonia (p < 0.0001) and 
angioedema was observed, with less frequent hypokalemia. 
Subgroup analysis suggested a better effect of the drug in 
patients with LVEF below 57%. Although the results of the 
PARAGON-HF study did not indicate the efficacy of ARNI 
in patients with HF and preserved left ventricular systolic 
function to improve survival, it improved clinical status, qua-
lity of life and kidney function when compared to patients 
receiving valsartan.
ISAR-REACT 5 — prasugrel versus ticagrelor 
in patients with acute coronary syndrome 
after coronaroplasty
ISAR-REACT 5 Study (The Intracoronary Stenting and 
Antithrombotic Regimen: Rapid Early Action for Coronary 
Treatment 5) caused a real sensation [3]. Two antiplatelet 
drugs (prasugrel and ticagrelor) added to acetylsalicylic 
acid (ASA) were compared in patients after acute coronary 
syndrome (ACS) requiring an invasive treatment strategy 
after coronary angiography, 85% of whom had coronaropla-
sty. The  patients with active bleeding, treated with antico-
agulants, after a stroke or transient ischaemic attack (TIA), 
with renal failure requiring dialysis, with acute or moderate 
liver failure, and using CYP3A drugs were excluded in this 
non-commercial study. 4,018 people were included in the 
study; 2012 received ticagrelor and 2006 prasugrel. The 
authors determined for the first time in a head-to-head 
study the impact of these drugs on mortality, ST-segment 
elevation myocardial infarction (STEMI), haemorrhagic and 
ischaemic stroke during 12 months of therapy. To the sur-
prise of the initiators of the study, there were significantly 
fewer (36%) adverse events in the prasugrel-treated group 
(6.9% vs. 9.3%, p = 0.006). When comparing each of the 
shown to be suitable for the treatment of HF regardless of 
the diabetes coexistence. The primary endpoint was seen 
in fewer people treated with inhibitor SGLT2 (386/16.3%, 
including 215 patients with diagnosed T2DM) compared to 
502/21.17% undergoing standard therapy (including 271 
with T2DM), which means a 26% risk reduction [hazard 
ratio (HR) = 0.74, p = 0.00001]. Listed as one of the prima-
ry endpoints, unplanned hospitalisation was significantly 
less common in patients treated with dapagliflozin (231 
patients required an additional hospital stay — 9.7%, vs. 
318 patients — 13.4% from the control group; HR = 0.7, 
p = 0.00003). Weaker but also statistically significant 
results were obtained in the area of deaths from cardio-
vascular causes — 227 patients (9.6%) who received the 
SGLT2 inhibitor died compared to 273 (11.5%) patients 
undergoing standard treatment (HR = 0.82, p = 0.029). 
Total deaths were also compared, showing lower mortality 
in the dapagliflozin group (11.6% vs. 13.9% in the control 
group; HR = 0.83, p = 0.022). Researchers defined the 
secondary endpoint as hospitalisation for HF or death from 
cardiovascular causes. Also, in this regard, the results of the 
study showed the benefits of using dapagliflozin (HR = 0.75, 
p = 0.00002). The authors also considered the severity of 
HF symptoms in accordance with the Kansas City Cardiomyo-
pathy Questionnaire (KCCQ) scale, demonstrating improve-
ment in the clinical condition after 8 months (p < 0.001) 
in the case of inhibitor SGLT2 treatment. Dapagliflozin had 
a neutral effect on renal function with no signs reported 
of the adverse effects of the study drug. Importantly, the 
protective effect in HF did not depend on the use of ARNI 
— it was identically strong in patients treated with and 
without sacubitril/valsartan, suggesting a different me-
chanism of action. The DAPA-HF study has already shown 
that adding dapagliflozin to standard therapy reduces the 
risk of exacerbation of HF symptoms, as well as improves 
clinical status, which is associated with a reduced number 
of hospitalisations and reduced cardiovascular mortality in 
HF patients with reduced LVEF also without T2DM, which is 
a breakthrough observation and means the identification 
of a new drug that improves prognosis in HF.
PARAGON-HF — angiotensin receptor  
neprilysin inhibitor in HF with  
intermediate and preserved LVEF?
Another study on HF, the results of which had been expected, 
was PARAGON-HF (Efficacy and Safety of ARNI Compared 
to Valsartan, on Morbidity and Mortality in Heart Failure 
Patients with Preserved Ejection Fraction) [2]. It compared 
the effects of treatment with angiotensin II receptor blocker 
(ARB) — valsartan 160 mg, and treatment with ARB and ne-
prilisin inhibitor (ARNI) — sacubitril/valsartan (97/103 mg) 
for 35 months in a difficult-to-treat group of patients with HF 
with intermediate and preserved LVEF. The study included 
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primary endpoint components individually, benefits were 
also seen in patients treated with prasugrel in regard to 
stent thrombosis. In the group of patients treated with 
prasugrel, there were insignificantly less (12%) incidents 
of major bleeding (determined by the Bleeding Academic 
Research Consortium scale — 4.8% vs. 5.4%, p = 0.46) 
compared to those treated with ticagrelor. ISAR-REACT 5 
demonstrated that treatment with prasugrel in patients 
with ACS reduces the risk of death, recurrent heart attack 
and stroke without increasing the risk of bleeding. These 
results come from study with a very well-planned protocol 
in which two antiplatelet drugs were compared for the first 
time in the context of percutaneous coronary intervention 
(PCI). The results of the ISAR-REACT 5 study emphasise the 
importance of solid evidence-based medicine, using direct, 
precise studies of relevant clinical groups, not stopping at 
indirect comparisons — using the results of separate trials 
with not necessarily identical characteristics.
THEMIS — dual antiplatelet therapy  
with ticagrelor versus ASA monotherapy  
in patients with stable CAD and T2DM
The attention of the participants was also focused on the 
THEMIS (The Effect of Ticagrelor on Health Outcomes 
in DiabEtes Mellitus Patients Intervention Study) study 
[4], which aimed to demonstrate the benefits of using 
ticagrelor (dual antiplatelet therapy with ASA) compared 
to a control group receiving only ASA in patients with 
T2DM treated for at least 6 months and stable CAD with 
no history of myocardial infarction. The primary endpoint 
was a risk of cardiovascular death, heart attack or stroke. 
19,220 patients were enrolled in the study, of whom 9,619 
received ticagrelor. The inclusion of ticagrelor significantly 
reduced the risk of a composite endpoint by 10% (HR = 0.9, 
p = 0.038). In the analysis of individual treatment goals, 
dual antiplatelet therapy reduced the number of myo-
cardial infarction (HR = 0.84, p = 0.029) and strokes 
(HR = 0.8, p = 0.038). Acute limb ischaemia was also rarer 
(HR = 0.45, p = 0.017). However, the primary safety-related 
endpoint proved unfavourable for dual therapy, which more 
than doubled the number of bleeding complications and 
the increased the risk of intracranial haemorrhage by 71%. 
A group of patients THEMIS-PCI (THEMIS-Percutaneous 
Coronary Intervention) [5] treated with the PCI was pro-
spectively separated from the group of patients included 
in the THEMIS study. This subgroup consisted of 5,558 
patients who underwent dual antiplatelet therapy and 
5,596 patients from the control group. In this subgroup, 
the inclusion of ticagrelor reduced the risk of a composite 
endpoint (cardiovascular death, myocardial infarction or 
stroke) by 15% (HR = 0.85, p = 0.013). In the analysis of 
individual treatment goals, dual antiplatelet therapy also 
reduced the number of heart attacks and strokes in the 
group of patients treated with PCI. When analysing each 
of the points, the risk of myocardial infarction was reduced 
by 20% (HR = 0.8, p = 0.027), STEMI by 68% (HR = 0.32, 
p < 0.0001) and stroke by 26% (HR = 0.74, p = 0.024). 
Comparing the composite endpoint including death, myo-
cardial infarction, ischaemic stroke, fatal bleeding and 
intracranial haemorrhage, it was demonstrated that the 
inclusion of ticagrelor reduced the risk by 15% (HR = 0.85, 
p = 0.005). Pharmacotherapy with ticagrelor (initially at 
2 × 90 mg, but in the later phase of the study reduced 
to 60 mg) in THEMIS in CAD and T2DM patients treated 
with prior PCI has also been shown to reduce the risk of 
cardiovascular death, MI and stroke despite the bleeding. 
The results of the study suggest that long-term, even last-
ing 3 years, ticagrelor therapy with ASA may become useful 
in patients with stable CAD and T2DM, especially those 
patients treated with percutaneous coronary angioplasty, 
with a high risk of thromboembolic events and a low risk 
of bleeding.
AFIRE — rivaroxaban monotherapy versus 
dual antiplatelet therapy in patients with 
CAD and atrial fibrillation
A recent study focused on the treatment of patients with 
CAD and co-existing atrial fibrillation. The aim of the Ja-
panese AFIRE study [6] was to compare the effectiveness 
of rivaroxaban treatment alone or in combination with 
antiplatelet agents. The study included 2,200 patients with 
CAD and atrial fibrillation (with CHADS2 ≥ 1) one year after 
coronary angioplasty or coronary artery bypass grafting, 
and those not requiring intervention with vasoconstriction 
exceeding 50%. The study excluded patients with a history 
of stent thrombosis, concomitant active tumour, and poorly 
controlled hypertension. Patients received rivaroxaban 
monotherapy at a “Far-Eastern” typical dose of 10–15/day, 
which corresponded to typical dosing in Caucasian pa-
tients, or in combination with one of the antiplatelet agents 
(also in modified dosing — ASA 81–100 mg, clopidogrel 
in 50–75 mg or prasugrel 2.5–3.75 mg). Finally, 1,005 
patients treated with rivaroxaban only and 968 undergoing 
dual antiplatelet therapy were randomised. Researchers 
assessed a composite endpoint including stroke, embolic 
complications, MI, unstable angina requiring revasculari-
zation, or death over a 23-month follow-up period. A 28% 
lower risk of composite endpoint was seen with rivaroxa-
ban alone (HR = 0.72, p < 0.001), as well as a 41% less 
bleeding event (HR = 0.59, p = 0.01). Taking into account 
the occurrence of cardiovascular incidents and mortality, 
rivaroxaban monotherapy significantly better protects 
patients who underwent coronary revascularization a year 
ago or earlier, which is the first evidence of the risk of the 
chronic combination of new anticoagulants with antipla-
telet agents.
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